BRCA2 and neoplasm: On the other hand, Annala et al. found shorter PFS in mutated patients treated with NHT in first line, first in a retrospective study and then in a prospective cohort exploring the predictive impact of BRCA2 and ATM mutations identified in circulating tumor DNA [9,23].